Dynamics of changes in serum albumin binding function and endogenous intoxication in patients with hypertension and comorbid states when using a hepatoprotector
DOI:
https://doi.org/10.11603/bmbr.2706-6290.2021.4.12593Keywords:
hypertension, non-alcoholic steatohepatitis, type 2 diabetes mellitus, serum albumin binding function, endogenous intoxication, AntralAbstract
Summary. Hypertension (HT) remains an important issue in modern medicine. In recent years, the study of related comorbid conditions has attracted attention. Nonalcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (DM) are among such common diseases of interest. The study of metabolic changes caused by such a combination will provide a better understanding of their pathogenesis and optimize treatment methods.
The aim of the study – to evaluate the changes in serum albumin binding function and endogenous intoxication (EI) when HT in combination with concomitant NASH and T2DM and to suggest ways of appropriate medical correction
Materials and Methods. Three groups of patients with HT stage 2–3 were examined. Group 1 included 28 patients with HT without concomitant diseases, group 2 – 48 patients with concomitant NASH, group 3 – 47 patients with NASH and type 2 diabetes. Groups 2 and 3, in turn, were divided into two subgroups (A and B): patients of subgroups A – received basic HT therapy and additional drug Antral 1 tablet 3 times a day for 60 days, subgroup B – only basic HT therapy. All patients underwent standard clinical examination, as well as serum albumin binding function and EI parameters: middle mass molecules (MMM) at a wavelength of 254 and 280 nm and erythrocyte intoxication index. The comparison group consisted of 25 almost healthy individuals (control group).
Results. An increase in EI levels was found according to all studied indicators in patients with HT without comorbidities. With concomitant NASH and NASH and type 2 diabetes – a significant decrease in binding function of serum albumin, as well as greater manifestations of endotoxicosis (p <0.05). Additional use of Antral in complex treatment contributed to an increase in serum albumin binding function and a decrease in the level of EI compared with patients who did not receive this hepatoprotector (p <0.05).
Conclusions. Signs of EI are observed when HT without concomitant pathology. These changes are more pronounced against the background of NASH and NASH and type 2 diabetes, as well as significantly reduced serum albumin binding function. The use of Antral hepatoprotector leads to increased levels of binding function of serum albumin and reduced endotoxicosis.
References
Lashkul ZV. [Features of the epidemiology of arterial hypertension and its complications at the regional level from 1999 to 2013]. Suchasni medychni tekhnolohii. 2014;2: 134. Ukrainian.
Andreychyn SM, Skirak ZS. [Effect of glutargine on serum albumin binding function and other indicators of liver function in acute toxic hydrazine hepatitis]. Medychna ta klinichna khimiia. 2014;4: 66-9. Ukrainian.
Vdovychenko VI, Kulchytskyy VV. [Hypertension in combination with type 2 diabetes: conflicting views on management tactics]. Ukrayinskyi terapevtychnyi zhurnal. 2015;1: 63-8. Ukrainian.
Drozdova IV, Babets AA, Stepanova LH, Omelnytska LV. [Morbidity, prevalence and disability due to hypertension: approaches to analysis and prediction]. Ukrainskyi kardiolohichnyi zhurnal. 2017;1: 85-93. Ukrainian.
Skirak ZS. [Indicators of endogenous intoxication and lipoperoxidation in the dynamics of acute toxic carbon tetrachloride hepatitis]. Infektsiini khvoroby. 2014;3: 89-92. Ukrainian.
Radchenko LM. [Liver condition in patients with hypertension and overweight]. Medychna hidrolohiia ta reabilitatsiia. 2009;3: 52-56. Ukrainian.
Leung AA, Daskalopoulou SS, Dasgupta K. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33(5): 557-76.
Stepanov YuM, Fylyppova AYu. [Clinical features of the course of non-alcoholic steatohepatitis depending on concomitant diseases]. Suchasna hastroenterolohiia. 2006;29.3: 4-7. Ukrainian.
Kiriyenko VT, Potiy VV. [The effectiveness of antral in patients with chronic hepatitis C]. Visnyk naukovykh doslidzhen. 2015;3: 28-30. Ukrainian.
Polunyna TE. [Non-alcoholic fatty liver disease]. Multyfaktornaya patologiya. 2013;13-14: 11-3.
Barle H, Januszkiewicz A, Hallstrom L. Albumin synthesis in humans increases immediately following the administration of endotoxin. Clin Sci (Lond). 2002;103(5): 525-31.
Skirak ZS. [Disorders of serum albumin binding in toxic hepatitis. Thesis. Ternopil: Ternopil National Med. Univer; 2016. Ukrainian.
Zvyahyntseva TD, Chernobay AY. [The use of Antral in the treatment of non-alcoholic steatohepatitis: present and future]. Chelovek I Lekarstvo – Kazakhstan. 2016;17(78): 84. Russian.
Babak OYa, Fadeenko HD, Kolesnykova EV. [Experience of using the drug Antral in the complex therapy of non-alcoholic fatty liver disease]. Consilium Medicum Ukraina. 2010;4(5): 22. Russian.
Samohalska OYe. [The effectiveness of the drug "Antral" in non-alcoholic fatty liver disease]. Suchasna hastroenterolohiia. 2009;5(49): 85. Ukrainian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Bulletin of Medical and Biological Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
